Brain-penetrant cancer therapies
RVL-102 RD oncology; RVL-103 RD oncology; undisclosed programs RD undisclosed
Reverie Labs is pioneering technology to develop next-generation cancer therapies. Computational chemistry and machine learning provide new tools for drug discovery. Reverie is using these methods to develop small molecule kinase inhibitors to treat cancer. The process involves prediction of important molecular properties for on-target drug binding, screening millions of compounds in their virtual libraries for hit identification and molecular dynamics to understand the energetics of bound ligands to their protein targets. Reverie also uses algorithmic molecular generation to ensure selective molecules are synthesizable, stable and tissue-penetrant. With this approach, Reverie will advance a pipeline of tissue-penetrant kinase inhibitors for oncology targets.
Cambridge, MA/ Hybrid|100+ days ago